JP2003535865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535865A5 JP2003535865A5 JP2002501900A JP2002501900A JP2003535865A5 JP 2003535865 A5 JP2003535865 A5 JP 2003535865A5 JP 2002501900 A JP2002501900 A JP 2002501900A JP 2002501900 A JP2002501900 A JP 2002501900A JP 2003535865 A5 JP2003535865 A5 JP 2003535865A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- ring
- composition
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001721 carbon Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019773 Hepatitis G Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20992900P | 2000-06-07 | 2000-06-07 | |
| US60/209,929 | 2000-06-07 | ||
| PCT/US2001/018243 WO2001094351A1 (en) | 2000-06-07 | 2001-06-05 | Caspase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003535865A JP2003535865A (ja) | 2003-12-02 |
| JP2003535865A5 true JP2003535865A5 (enExample) | 2008-07-03 |
Family
ID=22780912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002501900A Pending JP2003535865A (ja) | 2000-06-07 | 2001-06-05 | カスパーゼインヒビターおよびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7407964B2 (enExample) |
| EP (1) | EP1289993B9 (enExample) |
| JP (1) | JP2003535865A (enExample) |
| KR (1) | KR20030025235A (enExample) |
| AT (1) | ATE377010T1 (enExample) |
| AU (2) | AU7527901A (enExample) |
| CA (1) | CA2409015A1 (enExample) |
| DE (1) | DE60131160T2 (enExample) |
| ES (1) | ES2295171T3 (enExample) |
| IL (1) | IL152845A0 (enExample) |
| WO (1) | WO2001094351A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2369619A1 (en) | 1999-04-09 | 2000-10-19 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
| PT1163208E (pt) | 1999-08-06 | 2004-08-31 | Vertex Pharma | Inibidores de caspase e as suas utilizacoes |
| US6495522B1 (en) | 1999-08-27 | 2002-12-17 | Cytovia, Inc. | Substituted alpha-hydroxy acid caspase inhibitors and the use thereof |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| DE60131160T2 (de) * | 2000-06-07 | 2008-08-07 | Vertex Pharmaceuticals Inc., Cambridge | Caspase-inhibitoren und ihre verwendungen |
| EP1485107A1 (en) | 2002-02-11 | 2004-12-15 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| EP1499898A2 (en) * | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| PE20040728A1 (es) | 2002-06-28 | 2004-10-23 | Vertex Pharma | Inhibidores de caspasa |
| US7612091B2 (en) | 2002-12-20 | 2009-11-03 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2004058756A1 (en) | 2002-12-27 | 2004-07-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| JPWO2004073742A1 (ja) * | 2003-02-24 | 2006-06-01 | 第一製薬株式会社 | Ｂ型肝炎ウイルスｘ相互作用蛋白質の分解阻害剤 |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| IL158599A0 (en) * | 2003-10-26 | 2004-05-12 | Yeda Res & Dev | Methods of modulating hematopoiesis |
| RU2382780C2 (ru) * | 2004-02-27 | 2010-02-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы каспаз и их применение |
| AU2005223767B2 (en) * | 2004-03-12 | 2011-12-01 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
| PL217743B1 (pl) * | 2004-05-15 | 2014-08-29 | Vertex Pharma | Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw |
| CN1980658A (zh) | 2004-05-27 | 2007-06-13 | 沃泰克斯药物股份有限公司 | 治疗自身炎性疾病的ice抑制剂 |
| ES2312012T3 (es) * | 2004-09-17 | 2009-02-16 | Biomas Ltd. | Nuevos compuestos de telurio y su uso como inmunomodulares. |
| KR20080038369A (ko) * | 2005-07-28 | 2008-05-06 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제 억제제 프로드럭 |
| JP2009521458A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | トロンビン受容体アンタゴニストとしてのオキサゾロイソキノリン誘導体 |
| EP2288615B1 (en) | 2008-05-21 | 2017-06-21 | Genesis Technologies Limited | Selective caspase inhibitors and uses thereof |
| US8518942B2 (en) | 2008-08-06 | 2013-08-27 | Buck Institute For Research On Aging | Caspase inhibitors and uses thereof |
| EP2221299A3 (en) | 2009-02-11 | 2010-11-03 | Dr. Reddy's Laboratories Ltd. | Preparation of cilazapril intermediates |
| US9045524B2 (en) | 2009-05-21 | 2015-06-02 | Novagenesis Foundation | Selective caspase inhibitors and uses thereof |
| CN101580505B (zh) * | 2009-05-27 | 2014-09-10 | 沈阳药科大学 | 吡咯并[2，1-b]喹唑啉类天然产物的衍生物及其制备方法和用途 |
| US9365612B2 (en) | 2010-01-29 | 2016-06-14 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Caspase inhibitors |
| JP6006908B2 (ja) | 2010-11-05 | 2016-10-12 | ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ | Ｉｃｅ阻害化合物およびその使用 |
| DK2697246T3 (en) | 2011-04-15 | 2018-05-28 | Genesis Tech Limited | SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CN105636953B (zh) * | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
| MX2016014731A (es) | 2014-05-12 | 2017-05-04 | Conatus Pharmaceuticals Inc | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| KR20180101418A (ko) | 2015-12-31 | 2018-09-12 | 코나터스 파마슈티칼스, 인크. | 간 질환의 치료에서의 카스파제 억제제의 사용 방법 |
| MX2019003889A (es) | 2016-10-05 | 2019-08-12 | Novartis Ag | Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico. |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT377586B (de) * | 1981-06-30 | 1985-04-10 | Erba Farmitalia | Verfahren zur herstellung von substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)chinazolinen |
| US5552400A (en) * | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| JP2000501428A (ja) * | 1996-09-12 | 2000-02-08 | アイドゥン ファーマシューティカルズ，インコーポレイテッド | 酵素のｉｃｅ／ｃｅｄ−３プロテアーゼファミリーを阻害する新規な三環式化合物 |
| BR9712987A (pt) * | 1996-10-11 | 2000-04-18 | Warner Lambert Co | Inibidores de enzima de conversão de interleucina-1beta de sulfonamida |
| CA2268098A1 (en) * | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | Aspartate ester inhibitors of interleukin-1.beta. converting enzyme |
| AU1915399A (en) * | 1998-07-10 | 2000-02-01 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| DE60131160T2 (de) * | 2000-06-07 | 2008-08-07 | Vertex Pharmaceuticals Inc., Cambridge | Caspase-inhibitoren und ihre verwendungen |
-
2001
- 2001-06-05 DE DE60131160T patent/DE60131160T2/de not_active Expired - Lifetime
- 2001-06-05 EP EP01941972A patent/EP1289993B9/en not_active Expired - Lifetime
- 2001-06-05 AU AU7527901A patent/AU7527901A/xx active Pending
- 2001-06-05 KR KR1020027016636A patent/KR20030025235A/ko not_active Withdrawn
- 2001-06-05 JP JP2002501900A patent/JP2003535865A/ja active Pending
- 2001-06-05 AU AU2001275279A patent/AU2001275279B2/en not_active Ceased
- 2001-06-05 AT AT01941972T patent/ATE377010T1/de not_active IP Right Cessation
- 2001-06-05 IL IL15284501A patent/IL152845A0/xx unknown
- 2001-06-05 ES ES01941972T patent/ES2295171T3/es not_active Expired - Lifetime
- 2001-06-05 CA CA002409015A patent/CA2409015A1/en not_active Abandoned
- 2001-06-05 WO PCT/US2001/018243 patent/WO2001094351A1/en not_active Ceased
- 2001-06-07 US US09/877,832 patent/US7407964B2/en not_active Expired - Fee Related
-
2008
- 2008-07-01 US US12/165,952 patent/US7829561B2/en not_active Expired - Fee Related
-
2010
- 2010-09-16 US US12/883,424 patent/US7968716B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003534325A5 (enExample) | ||
| JP2005533825A5 (enExample) | ||
| JP2004509120A5 (enExample) | ||
| RU2005102094A (ru) | Ингибиторы каспазы и их применение | |
| JP2006513220A5 (enExample) | ||
| CA2393710A1 (en) | Caspase inhibitors and uses thereof | |
| DE68910421T2 (de) | DC-88A-Derivate. | |
| JP2003506389A5 (enExample) | ||
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| CA2536870A1 (en) | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists | |
| KR970015579A (ko) | 테트라졸 화합물 | |
| CA2447999A1 (en) | Caspase inhibitors and uses thereof | |
| NO178927C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive benzimidazoler | |
| JP2007524696A5 (enExample) | ||
| WO2007051081B1 (en) | Methods and compounds for preparing cc-1065 analogs | |
| JP2003525850A5 (enExample) | ||
| RU2005140657A (ru) | Ингибиторы каспаз и их применение | |
| JP2005509622A5 (enExample) | ||
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| JP2010516635A5 (enExample) | ||
| ZA95639B (en) | Substituted aromatic compounds | |
| JP2009502922A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| RU2007106935A (ru) | Производные гуанидина и их терапевтическое применение | |
| RU2008107576A (ru) | Пролекарства ингибитора каспазы |